Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Netherlands
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Nexpovio (selinexor) is an oral selective inhibitor of nuclear export (SINE) approved in the EU and UK for the treatment of multiple myeloma. It is used in combination with bortezomib and dexamethasone for adult patients who have received at least one prior therapy, or in combination with dexamethasone for adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Nexpovio is the EU/UK brand of the same active ingredient marketed in the United States as Xpovio.
Nexpovio blocks exportin 1 (XPO1), a protein that transports tumor suppressor proteins out of the cell nucleus. By inhibiting XPO1, Nexpovio helps restore the normal function of these tumor suppressor proteins within cancer cells, leading to cell cycle arrest and cancer cell death.
Nexpovio is intended for adult patients with multiple myeloma at various treatment stages, from those who have received one prior therapy to heavily pretreated patients with disease refractory to multiple drug classes.
In combination with bortezomib and dexamethasone, the typical dose is 100 mg orally once weekly. In combination with dexamethasone alone, the typical dose is 80 mg orally on Days 1 and 3 of each week.
Nexpovio does not use the FDA-style formal boxed warning format, as it is marketed under the EU/UK regulatory framework. However, patients and prescribers should be aware of the following important safety information.
Frequent blood count monitoring is required, particularly during the first two months of treatment, as thrombocytopenia is common and may require dose modification or platelet transfusion.
Patients should be monitored closely for signs of infection, and prophylactic measures may be considered based on individual risk factors.
Nausea and vomiting are common. Prophylactic antiemetic therapy, such as a 5-HT3 antagonist, is recommended before and during treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Nexpovio is marketed by Stemline Therapeutics B.V. (part of the Menarini Group) for the EU and UK markets. It is sourced through authorized European distribution channels for patients seeking named-patient import into India. Note: the same active ingredient, selinexor, is marketed in the United States under the brand Xpovio by Karyopharm Therapeutics.
Patients typically need a valid prescription from a treating hematologist-oncologist confirming multiple myeloma diagnosis and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an EU/UK-approved therapy for multiple myeloma, Nexpovio is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Nexpovio directly from authorized European pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Nexpovio does not require any special storage conditions, and this is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Nexpovio through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology-oncology care coordination and documentation for Nexpovio access.
Delhi's major hospitals assist patients with prescription support and documentation for Nexpovio.
Bangalore's specialist network offers access coordination for eligible multiple myeloma patients seeking Nexpovio.
Chennai-based hematology specialists coordinate Nexpovio access alongside comprehensive myeloma care.
Hyderabad's care institutions support patients pursuing Nexpovio therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Nexpovio.
Pune-based specialists assist with prescription support and Nexpovio treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Nexpovio.
Kochi's specialist units assist patients with the documentation needed for Nexpovio access.
Chandigarh's care centers support Nexpovio treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Nexpovio access process.
Lucknow-based centers assist patients pursuing Nexpovio therapy.
Bhubaneswar's institutions support access to Nexpovio for eligible patients.
Guwahati's specialists help coordinate Nexpovio access for patients across the Northeast.
Patients in other cities across India can also access Nexpovio through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: UK emc (SmPC)
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
